Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK) - Publikation - Autoren - KSSG Forschungsdatenbank

Publikation

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)

Wissenschaftlicher Artikel/Review - 08.06.2016

Matter-Walstra K, Ruhstaller Thomas, Klingbiel D, Schwenkglenks M, Dedes K J

Matter-Walstra, K

Ruhstaller, Thomas

Klingbiel, D

Schwenkglenks, M

Dedes, K J